In a phase 1, clinical trial repetitive locoregional dosing of human erb-b2 receptor tyrosine kinase 2 (HER2)-specific CAR-T cells to children and young adults with recurrent/refractory CNS tumors, including diffuse midline glioma. This evidence concerns the gene ERBB2 and central nervous system neoplasm.